PET

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Montag, Mai 6, 2024
Idiopathic pulmonary fibrosis, FVC, Investment, Hospital, Safety, Primary sclerosing cholangitis, Research, IPF, Collagen, Trial of the century, PET, Acceleration, DMD, Tumor microenvironment, PSC, European, Novartis, Week, Therapy, Vital capacity, Muscular dystrophy, Patient, TGF, Fibrosis, Cirrhosis, Integrin, Duchenne muscular dystrophy, Biomarker, Ethics committee, Massachusetts General Hospital, ELF, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2024 financial results.

Key Points: 
  • As part of the adaptive Phase 2b/3 implementation, the Phase 2b portion of BEACON-IPF was upsized from 267 patients to 360 patients.
  • Enrollment is progressing and we expect to complete enrollment of the upsized Phase 2b study expected in the first quarter of 2025.
  • The increase was due to higher operating expenses coupled with a decrease in collaboration revenues under the Novartis agreement during the quarter.
  • As of March 31, 2024, the Company had cash, cash equivalents and short-term investments of $483.9 million.

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on: 
Montag, Mai 6, 2024
Curium, PSMA, FDA, Cancer, Prostate, Food, Nuclear medicine, PET, Prostate cancer, European, INN, Patient, Physician, Medical imaging

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.

Key Points: 
  • PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
  • With today’s announcement, we are extremely proud to be improving the choice of diagnostic modalities available to our customers in Germany – ultimately for the benefit of patients with prostate cancer.”
    In Germany, prostate cancer is the most common cancer among men with around 63,400 new cases diagnosed nationwide every year.
  • Today’s announcement is part of the continued roll-out of PYLCLARI® across the European Union, which is now available for patients with prostate cancer in Greece, Italy, and the Netherlands.
  • In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat (18F) Injection) from the Food and Drug Administration (FDA) in May 2021.

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

Retrieved on: 
Mittwoch, Mai 8, 2024
Biotechnology, Technology, Health, Radiology, Pharmaceutical, Biometrics, Oncology, Health Technology, Software, Artificial Intelligence, Clinical Trials, PSMA, FDA, Safety, Hospital, Siemens Healthineers, Recurrence, PSA, PET, Artificial intelligence, PET/CT, RH, Prostate cancer, Patient, Metastasis, Physician, Radiopharmaceutical, Multimedia, Algorithm, Medical imaging

Siemens Healthineers plans to evaluate the data to enhance its analytics and artificial intelligence (AI)-based algorithms for prostate cancer image quantification and interpretation across its advanced PET/CT imaging software.

Key Points: 
  • Siemens Healthineers plans to evaluate the data to enhance its analytics and artificial intelligence (AI)-based algorithms for prostate cancer image quantification and interpretation across its advanced PET/CT imaging software.
  • Blue Earth Diagnostics has a long-standing relationship with Siemens Healthineers, a leading medical technology company pioneering breakthroughs in healthcare.”
    Dr. Gauden continued, “We are excited to provide these anonymized POSLUMA data from our LIGHTHOUSE trial, for use in enhancing the Siemens Healthineers syngo.via platform.
  • We also plan to make analytical data from the Phase 3 SPOTLIGHT trial of POSLUMA available in the future.
  • The study enrolled 391 patients at clinical sites in the United States and Europe.

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

Retrieved on: 
Mittwoch, Mai 8, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Randomized controlled trial, Safety, Food, Terminal, Survival, PET, ESMO, Patient, Physician, Biopsy, Head, Standard of care, Pharmaceutical industry

“Through this discussion and agreement with the FDA, we have achieved a tremendous milestone for people who are newly diagnosed with head and neck cancer.

Key Points: 
  • “Through this discussion and agreement with the FDA, we have achieved a tremendous milestone for people who are newly diagnosed with head and neck cancer.
  • The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone.
  • The FDA accepted the selection criteria and the proposed study design, which now permits CEL-SCI to enroll patients in the confirmatory study.
  • The goal of our smaller confirmatory study is to confirm these positive results in a prospectively defined target population.

Origin Materials Introduces World’s First Tethered PET Beverage Cap for Improved Recycling Circularity

Retrieved on: 
Dienstag, Mai 7, 2024
Sustainability, Environment, Other Manufacturing, Packaging, Recycling, Chemicals, Plastics, Green Technology, Manufacturing, PET, PCO, Carbon, HDPE, RPET, CSD

Origin Materials (“Origin”) (NASDAQ: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable materials, today announced another innovation in its PET caps and closures portfolio: the world’s first tethered PET cap.

Key Points: 
  • Origin Materials (“Origin”) (NASDAQ: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable materials, today announced another innovation in its PET caps and closures portfolio: the world’s first tethered PET cap.
  • “Tethered caps are designed to stay connected to the container and thereby improve cap collection rates for recycling.
  • Our PCO 1881-compatible cap is the first of its kind ever to be commercially produced with 100% PET.
  • Origin PET caps, including our tethered cap, may be produced with any kind of PET material, whether it’s virgin PET, recycled PET (rPET), or bio-based PET.

Bottles of the Year Program from Amcor Showcases the Best New Designs in Responsible Packaging

Retrieved on: 
Dienstag, Mai 7, 2024
Cosmetics, Packaging, Retail, Chemicals, Plastics, Health, Manufacturing, Consumer, Other Health, Supply Chain Management, Wine & Spirits, General Health, Supermarket, Other Consumer, Food, Beverage, AMCR, Wine, Sustainability, Empowerment, ASX, PET, Collection, Bottle, Multimedia, Marketing, AMC, Bottled water

Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced the launch of its Bottles of the Year program on National Packaging Design Day 2024.

Key Points: 
  • Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced the launch of its Bottles of the Year program on National Packaging Design Day 2024.
  • Annually, Amcor Rigid Packaging Bottles of the Year will recognize the best in innovative and responsible packaging designs that meet the latest trends in consumer preferences in the beverage, spirits & wine, food & dairy, home & personal care and healthcare segments.
  • View the full release here: https://www.businesswire.com/news/home/20240507690380/en/
    Annually, Amcor Rigid Packaging Bottles of the Year will recognize the best in innovative and responsible packaging designs that meet the latest trends in consumer preferences in the beverage, spirits & wine, food & dairy, home & personal care and healthcare segments.
  • (Photo: Business Wire)
    “We are excited to launch the Bottles of the Year program and celebrate the best in packaging design,” said Terry Patcheak, Vice President of R&D, Sustainability and Project Management at Amcor Rigid Packaging.

$175+ Bn Pharmaceutical Packaging Markets - Global Forecast to 2031: Growth Driven by Growing Counterfeiting, Implementation of Regulations, and Contract Packaging Trends - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Mai 7, 2024
Packaging, Pharmaceutical, Health, Manufacturing, Vaccination, PP, Glass, Safety, Route of administration, PET, Plastic, Paper, Conditional sentence, Metal, Syringe, Ageing, Temperature, Government, Ampoule, Growth, Polyvinyl chloride, Prevalence

The global pharmaceutical packaging market is projected to reach $176.54 billion by 2031 at a CAGR of 7.6% from 2024 to 2031.

Key Points: 
  • The global pharmaceutical packaging market is projected to reach $176.54 billion by 2031 at a CAGR of 7.6% from 2024 to 2031.
  • However, increasing instances of counterfeit packaging, increasing waste generation due to single-use packaging, and concerns over certain materials leaching into pharmaceutical preparations restrain the growth of this market.
  • North America is expected to account for the largest share of the pharmaceutical packaging market.
  • In the region in 2024, the U.S. is expected to account for the largest share of the pharmaceutical packaging market in North America.

Origin Materials Introduces World’s First CSD (Carbonated Soft Drink) PET Cap, the Lightest of its Kind Ever Produced Commercially

Retrieved on: 
Montag, Mai 6, 2024
Packaging, Recycling, Chemicals, Plastics, Environment, Manufacturing, Sustainability, PP, PET, PCO, Carbon, HDPE, RPET, Food, CSD, Multimedia

The initial product is the world’s lightest CSD (carbonated soft drink) cap compatible with the PCO 1881 neck finish, the first of its kind ever to be commercially produced with 100% PET and able to be produced with either virgin or recycled PET (rPET).

Key Points: 
  • The initial product is the world’s lightest CSD (carbonated soft drink) cap compatible with the PCO 1881 neck finish, the first of its kind ever to be commercially produced with 100% PET and able to be produced with either virgin or recycled PET (rPET).
  • View the full release here: https://www.businesswire.com/news/home/20240506783445/en/
    Origin CSD 1881 PET caps running on a commercial bottling line (Photo: Business Wire)
    “There are hundreds of different kinds of caps and closures in container packaging.
  • Origin’s first-of-its-kind, high-throughput production system will make the world’s first PET caps and closures at commercial scale, available beginning in Q4 2024.
  • To learn more about Origin’s PET caps and closures, visit our website or contact [email protected] .

Brook + Whittle awarded patent for light-blocking shrink sleeve innovation

Retrieved on: 
Mittwoch, Mai 8, 2024
Blockout, Sustainability, PET, Carbon footprint, USPP, Light, Patent, Brook, EPR, Non-governmental organization, Recycling, CPG, Renewable energy

GUILFORD, Conn., May 8, 2024 /PRNewswire/ -- Brook + Whittle is excited to announce that is has been awarded a U.S. patent for its GreenLabel™ BlockOut innovation, a recyclable light-blocking shrink sleeve solution for PET packaging.

Key Points: 
  • GUILFORD, Conn., May 8, 2024 /PRNewswire/ -- Brook + Whittle is excited to announce that is has been awarded a U.S. patent for its GreenLabel™ BlockOut innovation, a recyclable light-blocking shrink sleeve solution for PET packaging.
  • "At Brook + Whittle, we're committed to providing packaging solutions that balance aesthetics, performance, cost, and sustainability," says Tyler Matusevich, Director, Sustainability.
  • After eight years of R&D, we have developed a patented solution that utilizes a crystallizable shrink sleeve, our GreenLabel™ de-inkable inks, and a functional barrier coating.
  • We successfully conducted multiple commercial-scale trials to ensure the correct sortation and recyclability of this light-blocking shrink sleeve.

ENNOVI Optimizes EV Battery Module Cell Contacting System Design with Advanced Capabilities

Retrieved on: 
Mittwoch, Mai 8, 2024
CCS, Database, EV, Energy, Adhesive, PET, Cell, Research, Longevity, Original equipment manufacturer

SINGAPORE, May 8, 2024 /PRNewswire/ -- ENNOVI, a mobility electrification solutions partner, introduces an innovative cell contacting system (CCS) lamination approach. ENNOVI has qualified polyethylene terephthalate (PET) insulation foils and adhesives from multiple suppliers by testing them for their bond strength, durability, and environmental impact. As a result of this research, ENNOVI has a database of recommendations for the most effective material combinations, bypassing the trial-and-error approach that has long been a staple of the industry.

Key Points: 
  • Historically, the assembly of the CCS on battery cells has relied on cumbersome methods, including molded plastic trays and foams for positioning.
  • While effective for positioning the cells and collectors, these methods introduce unnecessary weight and complexity, especially as module sizes increase.
  • By optimizing the selection of PET foils and adhesives, ENNOVI is improving the structural integrity and lifespan of EV battery modules and reducing manufacturing cycle times and environmental footprint.
  • As the industry moves towards more sustainable, efficient manufacturing practices, ENNOVI's innovations are poised to lead the charge in the next generation of EV battery module design and assembly.